Tura Ferre

Tura Ferre

Auto-generated profile, based on publicly available information

Tura Ferre

Center of Animal Biotechnology and Gene Therapy, Universitat Autònoma de Barcelona, Bellaterra, Spain

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2012 in Diabetes
Verified
Journal Article
Open access
PDF file
IEIvet Elias
Ivet Elias
SFSylvie Franckhauser
Sylvie Franckhauser
TFTura Ferré
Tura Ferré
Laia VilàLaia Vilà
Laia Vilà
STSabrina Tafuro
Sabrina Tafuro
FBFatima Bosch
Fatima Bosch
During the expansion of fat mass in obesity, vascularization of adipose tissue is insufficient to maintain tissue normoxia. Local hypoxia develops and may result in altered adipokine expression, proinflammatory macrophage recruitment, and insulin resistance. We investigated whether an increase in adipose tissue angiogenesis could protect against obesity-induced hypoxia and, consequently, insulin resistance. Transgenic mice overexpressing vascular endothelial growth factor (VEGF) in brown adipose tissue (BAT) and white adipose tissue (WAT) were generated. Vessel formation, metabolism, and inflammation were studied in VEGF transgenic mice and wild-type littermates fed chow or a high-fat diet. Overexpression of VEGF resulted in increased blood vessel number and size in both WAT and BAT and protection against high-fat diet–induced hypoxia and obesity, with no differences in food intake. This was associated with increased thermogenesis and energy expenditure. Moreover, whole-body insulin sensitivity and glucose tolerance were improved. Transgenic mice presented increased macrophage infiltration, with a higher number of M2 anti-inflammatory and fewer M1 proinflammatory macrophages than wild-type littermates, thus maintaining an anti-inflammatory milieu that could avoid insulin resistance. These studies suggest that overexpression of VEGF in adipose tissue is a potential therapeutic strategy for the prevention of obesity and insulin resistance.

1 August 1996 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
TFTura Ferre
Tura Ferre
EREfren Riu
Efren Riu
FBFatima Bosch
Fatima Bosch
AVAlfons Valera
Alfons Valera

24 April 2008 in Diabetologia
Verified
Journal Article
Closed access
PDF file
SFSylvie Franckhauser
Sylvie Franckhauser
IEI. Elias
I. Elias
VSV. Rotter Sopasakis
V. Rotter Sopasakis
TFT. Ferré
T. Ferré
INI. Nagaev
I. Nagaev
USUlf Smith
Ulf Smith

9 July 1996 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
TFT Ferre
T Ferre
APA Pujol
A Pujol
ERE Riu
E Riu
FBF Bosch
F Bosch
AVA Valera
A Valera
Hyperglycemia is a common feature of diabetes mellitus. It results from a decrease in glucose utilization by the liver and peripheral tissues and an increase in hepatic glucose production. Glucose phosphorylation by glucokinase is an initial event in glucose metabolism by the liver. However, glucokinase gene expression is very low in diabetic animals. Transgenic mice expressing the P-enolpyruvate carboxykinase/glucokinase chimeric gene were generated to study whether the return of the expression of glucokinase in the liver of diabetic mice might prevent metabolic alterations. In contrast to nontransgenic mice treated with streptozotocin, mice with the transgene previously treated with streptozotocin showed high levels of both glucokinase mRNA and its enzyme activity in the liver, which were associated with an increase in intracellular levels of glucose 6-phosphate and glycogen. The liver of these mice also showed an increase in pyruvate kinase activity and lactate production. Furthermore, normalization of both the expression of genes involved in gluconeogenesis and ketogenesis in the liver and the production of glucose and ketone body by hepatocytes in primary culture were observed in streptozotocin-treated transgenic mice. Thus, glycolysis was induced while gluconeogenesis and ketogenesis were blocked in the liver of diabetic mice expressing glucokinase. This was associated with normalization of blood glucose, ketone bodies, triglycerides, and free fatty acids even in the absence of insulin. These results suggest that the expression of glucokinase during diabetes might be a new approach to the normalization of hyperglycemia.

1 December 2003 in Diabetologia
Verified
Journal Article
Closed access
PDF file
TFT. Ferre
T. Ferre
ERE. Riu
E. Riu
SFSylvie Franckhauser
Sylvie Franckhauser
JAJ. Agudo
J. Agudo
FBF. Bosch
F. Bosch

16 November 2013 in Diabetes
Verified
Journal Article
Open access
VJVERONICA JIMENEZ
VERONICA JIMENEZ
SMSergio Muñoz
Sergio Muñoz
ECEstefania Casana
Estefania Casana
CMCristina Mallol
Cristina Mallol
IEIvet Elias
Ivet Elias
FBFatima Bosch
Fatima Bosch
Adipose tissue is pivotal in the regulation of energy homeostasis through the balance of energy storage and expenditure and as an endocrine organ. An inadequate mass and/or alterations in the metabolic and endocrine functions of adipose tissue underlie the development of obesity, insulin resistance, and type 2 diabetes. To fully understand the metabolic and molecular mechanism(s) involved in adipose dysfunction, in vivo genetic modification of adipocytes holds great potential. Here, we demonstrate that adeno-associated viral (AAV) vectors, especially serotypes 8 and 9, mediated efficient transduction of white (WAT) and brown adipose tissue (BAT) in adult lean and obese diabetic mice. The use of short versions of the adipocyte protein 2 or uncoupling protein-1 promoters or micro-RNA target sequences enabled highly specific, long-term AAV-mediated transgene expression in white or brown adipocytes. As proof of concept, delivery of AAV vectors encoding for hexokinase or vascular endothelial growth factor to WAT or BAT resulted in increased glucose uptake or increased vessel density in targeted depots. This method of gene transfer also enabled the secretion of stable high levels of the alkaline phosphatase marker protein into the bloodstream by transduced WAT. Therefore, AAV-mediated genetic engineering of adipose tissue represents a useful tool for the study of adipose pathophysiology and, likely, for the future development of new therapeutic strategies for obesity and diabetes.